Section 216-RICR-40-20-1.10 - Surveys and Monitoring1.10.1Testing for Leakage or Contamination of Sealed SourcesA. The licensee in possession of any sealed source shall assure that:1. Each sealed source, except as specified in §1.10.1(B) of this Part, is tested for leakage or contamination and the test results are received before the sealed source is put into use unless the licensee has a certificate from the transferor indicating that the sealed source was tested within six (6) months before transfer to the licensee.2. Each sealed source that is not designed to emit alpha particles is tested for leakage or contamination at intervals not to exceed six (6) months or at alternative intervals approved by the Agency, after evaluation of information specified by §7.6.17 of this Subchapter, another Agreement State or the U.S. Nuclear Regulatory Commission.3. Each sealed source that is designed to emit alpha particles is tested for leakage or contamination at intervals not to exceed three (3) months or at alternative intervals approved by the Agency, after evaluation of information specified by §7.6.17 of this Subchapter, another Agreement State or the U.S. Nuclear Regulatory Commission.4. For each sealed source that is required to be tested for leakage or contamination, at any other time there is reason to suspect that the sealed source might have been damaged or might be leaking, the licensee shall assure that the sealed source is tested for leakage or contamination before further use.5. Tests for leakage for all sealed sources, except brachytherapy sources manufactured to contain radium, shall be capable of detecting the presence of one hundred eighty-five (185) Bq (five one thousandths (0.005) µCi) of radioactive material on a test sample. Test samples shall be taken from the sealed source or from the surfaces of the container in which the sealed source is stored or mounted on which one might expect contamination to accumulate. For a sealed source contained in a device, test samples are obtained when the source is in the "off" position.6. The test for leakage for brachytherapy sources manufactured to contain radium shall be capable of detecting an absolute leakage rate of thirtyseven (37) Bq (one one thousandth (0.001) µCi) of radon-222 in a twenty-four (24) hour period when the collection efficiency for radon-222 and its daughters has been determined with respect to collection method, volume and time.7. Tests for contamination from radium daughters shall be taken on the interior surface of brachytherapy source storage containers and shall be capable of detecting the presence of one hundred eighty-five (185) Bq (five one thousandths (0.005) µCi) of a radium daughter which has a halflife greater than four (4) days.B. A licensee need not perform test for leakage or contamination on the following sealed sources: 1. Sealed sources containing only radioactive material with a half-life of less than thirty (30) days;2. Sealed sources containing only radioactive material as a gas;3. Sealed sources containing three and seven tenths (3.7) MBq (one hundred (100) µCi) or less of beta or photon-emitting material or three hundred seventy (370) kBq (ten (10) µCi) or less of alpha-emitting material;4. Sealed sources containing only hydrogen-3;5. Seeds of iridium-192 encased in nylon ribbon; and6. Sealed sources, except teletherapy and brachytherapy sources, which are stored, not being used and identified as in storage. The licensee shall, however, test each such sealed source for leakage or contamination and receive the test results before any use or transfer unless it has been tested for leakage or contamination within six (6) months before the date of use or transfer. No sealed source shall be stored for a period of more than ten (10) years without being tested for leakage and/or contamination.C. Tests for leakage or contamination from sealed sources shall be performed by persons specifically authorized by the Agency, another Agreement State or the U.S. Nuclear Regulatory Commission to perform such services.D. Records of tests for leakage or contamination of sealed sources required by §1.10.1 of this Part shall be kept in units of becquerel or microcurie and maintained for inspection by the Agency for five (5) years after the records are made.E. The following shall be considered evidence that a sealed source is leaking: 1. The presence of one hundred eighty-five (185) Bq (five one thousandths (0.005) µCi) or more of removable contamination on any test sample; or2. Leakage of thirty-seven (37) Bq (one one thousandth (0.001) µCi) of radon-222 per twenty-four (24) hours for brachytherapy sources manufactured to contain radium.F. The licensee shall immediately withdraw a leaking sealed source from use and shall take action to prevent the spread of contamination. The leaking sealed source shall be repaired or disposed of in accordance with this Part.G. The licensee shall file a report within five (5) working days with the Agency if the test for leakage or contamination indicates a sealed source is leaking or contaminated. The report shall include the equipment involved, the test results and the corrective action taken.1.10.2General Survey and Monitoring RequirementsA. For the purpose of this Part, general survey and monitoring requirements are defined by 10 C.F.R. § 20.1501.B. Exposure of a personnel monitoring device to deceptively indicate a dose delivered to an individual is prohibited.1.10.3Conditions Requiring Individual Monitoring of External and Internal Occupational DoseA. For the purpose of this Part, conditions requiring individual monitoring of external and internal occupational dose are defined by 10 C.F.R. § 20.1502.B. Individuals wearing a protective apron, when personnel monitoring is otherwise required by this Subchapter, shall position their individual monitoring devices as follows: 1. An individual monitoring device used for the dose to an embryo/fetus of a declared pregnant woman, pursuant to §1.7.8 of this Part, shall be located under the protective apron at the waist. a. It is recognized that, in the specific work environment of medical fluoroscopic equipment, the dose to the embryo/fetus is overestimated by the individual monitoring device because of the overlying tissue of the pregnant individual. A medical physicist who is registered with the Agency pursuant to § 3.6 of this Subchapter as a Provider of Diagnostic X-Ray Physics Services should be consulted to determine the dose to the embryo/fetus for the rare occasion in which this individual monitoring device has a monthly reported dose equivalent value in excess of five tenths (0.5) mSv (fifty (50) mrem). Therefore, for purposes of this Part, the value to be used for determining the dose to an embryo/fetus pursuant to §1.7.8 of this Part for occupational exposure to radiation from medical fluoroscopic equipment may be the value reported by the individual monitoring device worn at the waist underneath the protective apron which has been corrected for the particular individual and her work environment by the above referenced medical physicist.2. An individual monitoring device used for eye dose equivalent shall be located at the neck, or an unshielded location closer to the eye, outside the protective apron.3. When only one individual monitoring device is used to determine the effective dose equivalent for external radiation pursuant to §1.7.1(B) of this Part, it shall be located at the neck outside the protective apron. When a second individual monitoring device is used, for the same purpose, it shall be located under the protective apron at the waist. The second individual monitoring device is required for a declared pregnant woman.C. An individual monitoring device used for monitoring the dose to the extremities, to demonstrate compliance with §1.7.1(A) of this Part, shall be worn on the extremity likely to receive the highest exposure. Each individual monitoring device shall be oriented to measure the highest dose to the extremity being monitored.216 R.I. Code R. § 216-RICR-40-20-1.10
Adopted effective 1/1/2019
Amended effective 5/25/2022